Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma.
This study was designed to determine the level of survivin expression and its clinical significance as a prognostic factor in gastrointestinal stromal sarcoma (GIST). Twenty patients (12 males and 8 females) ranging in age from 25 to 72, with a median age of 53 were evaluated. Failure of TKI treatment was higher in the survivin-positive group (p=0.06). The rate of metastasis was significantly higher in the survivin positive group vs. the negative group (80% vs. 30%, p=0.18). The median overall survival (OS) time was 114 (range 29-199)months, and the median disease-free survival (DFS) time was 88 (range 40-135) months. The median progression-free survival (PFS) time was 40 (range 24-55) months. Further, a comparison of patients with survivin positive versus negative tumors, revealed no significant difference for OS, DFS, and PFS (p=0.45, p=0.19, p=0.55, respectively), number of mitoses in 50 HPF (p=0.14), and tumor size (p=0.94). In conclusion, survivin was highly expressed in GISTs, although we found no correlation between survivin expression and PFS, DFS and OS, survivin may be a predictive marker in GISTs for disease progression. We believe that additional studies are warranted to determine the clinical significance of survivin expression as a prognostic or predictive marker in patients with GIST.
Gazi University Medical Faculty, Department Of Medical Oncology, Ankara, Turkey.
Meltem
M
Baykara
Murat
M
Akkus
Ramazan
R
Yildiz
Ipek Isik
II
Gonul
Ayse
A
Dursun
Ugur
U
Coskun
Mustafa
M
Benekli
Alper
A
Sevinc
Faysal
F
Dane
Suleyman
S
Buyukberber
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D046152:Gastrointestinal Stromal Tumors / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use; D051034:Inhibitor of Apoptosis Proteins / Q000096:biosynthesis*; D008297:Male; D008875:Middle Aged; D008938:Mitosis; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012189:Retrospective Studies; D000077210:Sunitinib; D000077022:Survivin; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D001549:Benzamides; D014408:Biomarkers, Tumor; D007211:Indoles; D051034:Inhibitor of Apoptosis Proteins; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000077022:Survivin; D000068877:Imatinib Mesylate; C498826:nilotinib; D000077210:Sunitinib